Uncategorized

[Nature Biomedical Engineering] Investigators developed a tissue-clearing 3D quantitative approach integrated with simultaneous mRNA and protein detection. Such protocol aims to characterize the bone microenvironment and reveal quantitative differences in the osteo-sinusoidal niche of aged and young human MSCs.

[Stem Cell Research & Therapy] Researchers discovered that human umbilical cord MSCs alleviate lipopolysaccharide-induced glycocalyx damage in pulmonary vascular endothelial cells by secreting Cxcl12, which activates the downstream receptor CXCR4, providing a therapeutic effect for acute respiratory distress syndrome.

[Stem Cell Research & Therapy] Scientists investigated the role of autophagy-related gene 5 (ATG5) in the antioxidant capacity and evaluate the therapeutic effect of ATG5-engineered MSCs for colitis treatment.

[Stem Cell Research & Therapy] Researchers explored the effects of bone marrow derived MSCs on ovarian stromal cells in a premature ovarian failure (POF) modelIn vivo experiments revealed that cyclophosphamide-induced premature ovarian failure rats exhibited irregular estrous cycles and increased deposition of interstitial collagen fibers.

[Targeted Oncology] The FDA has granted orphan drug designation to eftilagimod alfa, an investigational immunotherapy, for the treatment of soft tissue sarcoma. The Phase II trial met its primary end point tumor of hyalinization/fibrosis across multiple sarcoma subtypes with the combination of eftilagimod alfa, radiotherapy, and pembrolizumab.

[NatureCell Co, Ltd. (ACCESS Newswire, Inc.)] NatureCell Co, Ltd. announced the planned reactivation and acceleration of its previously cleared Phase IIb clinical trial for Alzheimer's disease under an Investigational New Drug authorization from the US FDA. The study is designed to evaluate autologous adipose-derived MSCs administered as a potential disease-modifying therapy.

[Nature Communications] Researchers used single-cell RNA-sequencing to quantify genetic contributions to cis-regulatory variation in 361,119 peripheral blood mononuclear cells of 63 acute COVID-19 patients, 39 convalescent samples, and 106 healthy controls.

[Nature Structural & Molecular Biology] Investigators showed that, following ACE2 engagement of the SARS-CoV-2 spike inducing the early fusion intermediate conformation , TMPRSS2 cleaves the R815 S2′ site and promotes fusogenic conformational changes leading to viral entry.

[Journal of Virology] Scientists first investigated the resistance profile of simnotrelvir, an approved anti-SARS-CoV-2 drug that targets 3CLpro. They found that the T21I/E166A mutations in 3CLpro equally emerged when SARS-CoV-2 was passaged in the cells with increasing concentrations of simnotrelvir.

[Nature Cancer] Scientists discovered that STING agonist expanded regulatory B cells depended on PI3Kγ but not PI3Kδ in pancreatic cancer, whereas activating myeloid cells were independent of PI3Kγ.

[Immunology] The authors discuss the interplay between the mucosal barrier and Tregs in the lung cancer immune microenvironment, with a focus on the functional balance between Treg-mediated immunosuppression and mucosal maintenance.

[Nature Biotechnology] The first-of-its-kind genetic medicine treats a rare and profound otoferlin-related hearing loss, and will be made available by Regeneron for free in the United States.